Abirapro 250 mg tablet is used in the treatment of cancer of prostrate gland . it may also be used to treat others conditions as determined by the doctor. It is sometimes used with other medications as part of combination chemotherapy.
It is a medication that blocks the effect of testosterone hormone . it treats prostrate cancer,which is develops in the prostrate gland ,a part of reproductive system in men. One can take this medication by mouth with a glass of water.
WHAT IS ABIRAPRO 250 MG?
Abirapro 250 mg tablet is a prescription anticancer medication used in the treatment of prostrate cancer in adult men. It contains abiraterone acetate ,which works by reducing the production of androgen’s (male hormones) that promote the growth of prostrate cancer cells. It is used under oncologist supervision as part of a comprehensive prostrate cancer treatment plan. It is usually given with steroid medication to lower the chances of side effects. This medicine is not for use in women or children . effective contraception must be taken throughout the treatment.
UNDERSTANDING PROSTRATE CANCER
Prostrate cancer is a common, often slow- growing malignancy of the male reproductive gland that is highly treatable if detected early. It commonly effects men over 65, with symptoms like frequent urination, blood in urine or semen, and pain. Treatment options range from active surveillance to surgery ,radiation and hormone therapies.
ROLE OF MALE HORMONE IN CANCER GROWTH
Male hormones primarily testosterone and dihydrotestosterone (DHT) fuel the growth of prostrate cancer cells by binding to and activating the androgen receptor, which are essential for tumor progression ,promoting the use of androgen deprivation therapy(ADT) to lower hormone levels,shrink tumors and slow disease progression.
Hormone therapy for prostrate cancer is used to block the hormone testosterone in the body ,which fuels the growth of prostrate cancer cells. It can help shrink cancer and slow the growth of cancer, but it is not a cure for prostate cancer. It might be a choice at different times for different reasons during prostrate cancer treatment.
HOW ABIRAPRO 250 MG WORKS?
Abirapro 250 mg works by inhabiting the CYP17 enzyme to significantly reduce androgen (testosterone) production in the body ,which fuels prostrate cancer growth. It is a prescription, oral, androgen biosynthesis inhibitor used with prednisone to treat metastatic , castration-resistant prostrate cancer. It blocks the CYP17 enzyme in the adrenal glands ,testes , and the prostrate tumour itself, effectively stopping the cancer from getting the hormones it needed to grow.
WHAT ARE THE INDICATIONS OF ABIRAPRO 250MG ?
l METASTATIC CASTRATION-RESISTANT PROSTRATE CANCER (mCRPC)
Metastatic castration -resistance prostrate cancer is an advanced ,incurable stage where cancer spreads beyond the prostrate and progresses despite low testosterone levels. It is a leading cause of cancer death, with a median survival of approximately 14-30 months . treatment focuses on prolonging life and managing symptoms using hormonal therapies ,immunotherapy and targeted therapies .
l METASTATIC HORMONE -SENSITIVE PROSTRATE CANCER (mHSPC)
Metastatic hormone -sensitive prostrate cancer is an advanced, currently incurable cancer that has spread beyond the prostate but still responds to testosterone lowering therapies. Treatment involves intensified ,multi-drug regimens -specifically androgen deprivation therapy (ADT) combined with androgen receptor pathway inhibitor (ARPIs) or chemotherapy significantly improving survival compared to older treatments.
l USED WITH PREDNISONE
Prednisone is a standard ,essential component in treating advanced, metastatic castration-resistant prostrate cancer (mCRPC) ,commonly paired with abirpro . it reduces PSA levels ,relives pain from bone metastases , improves quality of life and manages side effects from other treatment.
CONCLUSION : Abirapro 250 mg is an effective, high-value treatment for advanced prostrate cancer ,primarily used with steroids to inhibit androgen production. Low-dose(250 mg) with food is considered a cost-effective ,clinically equivalent alternative to standard doses, significantly reducing cost and improving patient compliance while effectively slowing tumour growth.